Press releaseBusiness Wire
Guided Therapeutics
GTHP · OTC
$0.19+$0.03 (+18.75%)TodayMarket closed ·
Prev close $0.16
Latest news
- Press releaseBusiness Wire
Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese Distributor
- Press releaseBusiness Wire
Guided Therapeutics Announces New Agreement with Distribution Partner Yuanshuo Medical Instruments Corporation
- Press releaseBusiness Wire
Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA
- Press releaseBusiness Wire
Guided Therapeutics Provides Updates on FDA Application Study Results, 2025 Earnings Increase and Successful Warrant Offering
- Press releaseBusiness Wire
Analysis of Guided Therapeutics' FDA Study Data Reveals Compelling Clinical Need for LuViva
- Press releaseBusiness Wire
Guided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor
- Press releaseBusiness Wire
Guided Therapeutics Inks Initial $200,000 Deal with New Distribution Partner Yuanshuo Medical Instruments Corporation
- Press releaseBusiness Wire
Guided Therapeutics Receives $70,000 -- Its Second of Nine Payments Totaling $700,000 -- from New Chinese Distribution Partner that Provides Products for 2 Million Annual Cervical Cancer Screenings
- Press releaseBusiness Wire
Guided Therapeutics Provides Update on Completion of US FDA Clinical Trial
- Press releaseBusiness Wire
Guided Therapeutics Makes Initial Shipment to New Chinese Distribution Partner Hangzhou Dongye Medical Technology, Ltd.
- Press releaseBusiness Wire
Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor
- Press releaseBusiness Wire
Guided Therapeutics Receives $100,000 from SMI's Investment Partners to Continue Commercialization Process of LuViva in China
- Press releaseBusiness Wire
Guided Therapeutics Receives Order and Full Payment From Indonesia for 4 LuViva Systems and 1,200 Disposables
- Press releaseBusiness Wire
Guided Therapeutics Announces Filing of Application for NMPA Approval to Market and Sell LuViva in China
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.